0001209191-19-018958.txt : 20190312 0001209191-19-018958.hdr.sgml : 20190312 20190312181327 ACCESSION NUMBER: 0001209191-19-018958 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190308 FILED AS OF DATE: 20190312 DATE AS OF CHANGE: 20190312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heartlein Michael CENTRAL INDEX KEY: 0001744680 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 19676342 MAIL ADDRESS: STREET 1: C/O TRANSLATE BIO, INC. STREET 2: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-08 0 0001693415 Translate Bio, Inc. TBIO 0001744680 Heartlein Michael C/O TRANSLATE BIO, INC. 29 HARTWELL AVE LEXINGTON MA 02421 0 1 0 1 Chief Scientific Officer Chief Technical Officer Stock Option (right to buy) 7.95 2019-03-08 4 A 0 150000 0.00 A 2029-03-07 Common Stock 150000 150000 D This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. /s/ Paul D. Burgess, as attorney-in-fact 2019-03-12